Geir Frode Øy
- PhD student; Siv.Ing./MSc
- +47 22 78 17 87
Publications 2024
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer (in press)
DOI 10.1038/s41416-024-02875-5, PubMed 39390250
Publications 2023
Liver X receptors induce antiproliferative effects in basal-like breast cancer
Mol Oncol, 17 (10), 2041-2055
DOI 10.1002/1878-0261.13476, PubMed 37341140
Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
Front Oncol, 13, 1040665
DOI 10.3389/fonc.2023.1040665, PubMed 36910663
Publications 2022
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
Br J Cancer, 127 (11), 1939-1953
DOI 10.1038/s41416-022-01973-6, PubMed 36097178
Publications 2021
Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
Biomacromolecules, 22 (10), 4169-4180
DOI 10.1021/acs.biomac.1c00662, PubMed 34542998
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
Nanomaterials (Basel), 11 (5)
DOI 10.3390/nano11051140, PubMed 33924869
Publications 2020
Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
Cancers (Basel), 12 (7)
DOI 10.3390/cancers12071719, PubMed 32605315
Publications 2019
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681
Publications 2016
MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma
Oncotarget, 7 (34), 55128-55140
DOI 10.18632/oncotarget.10422, PubMed 27391157
Publications 2012
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275
Publications 2010
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500
Publications 2009
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847